(E)-4-((1-(3-(8-(tert-butyl)-3,3-dimethyl-3,11-dihydropyrano[3,2-a]carbazol-5-yl)acryloyl)pyrrolidin-2-yl)methoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide

ID: ALA5275497

Chembl Id: CHEMBL5275497

Max Phase: Preclinical

Molecular Formula: C37H38N4O7S

Molecular Weight: 682.80

Associated Items:

Names and Identifiers

Canonical SMILES:  CC1(C)C=Cc2c(c(/C=C/C(=O)N3CCCC3COc3no[n+]([O-])c3S(=O)(=O)c3ccccc3)cc3c2[nH]c2ccc(C(C)(C)C)cc23)O1

Standard InChI:  InChI=1S/C37H38N4O7S/c1-36(2,3)24-14-15-30-28(21-24)29-20-23(33-27(32(29)38-30)17-18-37(4,5)47-33)13-16-31(42)40-19-9-10-25(40)22-46-34-35(41(43)48-39-34)49(44,45)26-11-7-6-8-12-26/h6-8,11-18,20-21,25,38H,9-10,19,22H2,1-5H3/b16-13+

Standard InChI Key:  KLNOTNRFNIJSIW-DTQAZKPQSA-N

Alternative Forms

  1. Parent:

    ALA5275497

    ---

Associated Targets(Human)

MDA-MB-231 (73002 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCI-H460 (60772 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HeLa (62764 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 682.80Molecular Weight (Monoisotopic): 682.2461AlogP: 6.34#Rotatable Bonds: 7
Polar Surface Area: 141.67Molecular Species: NEUTRALHBA: 8HBD: 1
#RO5 Violations: 2HBA (Lipinski): 11HBD (Lipinski): 1#RO5 Violations (Lipinski): 3
CX Acidic pKa: CX Basic pKa: CX LogP: 5.79CX LogD: 5.79
Aromatic Rings: 5Heavy Atoms: 49QED Weighted: 0.15Np Likeness Score: 0.17

References

1. Zang Y, Huang L, Chen X, Li C, Ma J, Chen X, Zhang D, Lai F..  (2022)  Novel nitric oxide-releasing derivatives of pyranocarbazole as antitumor agents: Design, synthesis, biological evaluation, and nitric oxide release studies.,  244  [PMID:36270090] [10.1016/j.ejmech.2022.114832]

Source